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ディリサラ アンジャネユル 
Gene therapy emerged as a potential tool for treatment of both congenital and acquired diseases 
including intractable cancers by means of transducing therapeutic proteins. To realize this concept of 
gene therapy through systemic application, a gene delivery system with stealth surface is required to 
circumvent biological interferences including nuclease attack, opsonin adsorption followed by 
reticuloendothelial system (RES) capture. In view of these requirements, Kataoka et al. have developed 
poly(ethylene glycol) (PEG) shielded gene delivery system as promising formulation based on 
electrostatic self-assembly of PEG-polycation block copolymers and plasmid DNA (pDNA) to form 
polyplex micelle (PM), where pDNA is packaged into rod-shaped bundle as core and PEG as shell. The 
PEG shell effectively prevents interactions with biological interferences capable for systemic 
applications; nevertheless, the blood retention of this prototype PM was unsatisfactory to obtain 
sufficient therapeutic activity, thus demanded modifications to reinforce PM stability in bloodstream. 
For this purpose, environment-responsive disulfide cross-links were introduced into the core of PMs 
(cross-linked PMs: CPMs) (10% thiolation degree was used based on previous optimization) fabricated 
from PEG-poly(L-lysine) (PEG-PLys) for preventing unfavorable dissociation. Indeed CPMs exhibited 
better blood circulation than that of PMs without cross-linking (non-cross-linked PMs: non-CPMs). 
Besides core cross-linking, the role of PEG shell in achieving promoted blood circulation was 
demonstrated, where higher PEG crowdedness was found to be settle on PMs prepared from lower 
degree (DP) of PLys segment of PEG-PLys certainly exhibited better blood circulation property. 
Moreover, PMs of lower PLys DP exhibited promoted transcription efficiency. These studies suggested 
that applying cross-linking into the PMs prepared from lower PLys DP would be a suitable formulation 
for systemic applications. However, upon considering transfection activity, the highly PEG crowded 
PMs may in turn be disadvantageous because the reduced affinity of these PMs with cellular membrane 
may result in precluded cellular uptake. Additionally, it was found that PLys DP affects the rod-length 
of PMs: lower PLys DP resulted in longer rod-lengths (several 100-nm) while higher PLys DP resulted 
in shorter rod-lengths (≈70-nm). Likely, these longer rod PMs may be unfavorable to obtain efficient 
cellular uptake because each endocytic pathway has upper size limit with regard to their vesicle 
diameter. Furthermore, relatively lower binding affinity of lower PLys DP to pDNA than that of higher 
PLys DP might decrease structural stability of the PMs thus may influence transfection efficiency. 
Even though such impaired stability and unfavorable high PEG shielding for cellular uptake may be 
overcome by applying the cross-linking and the ligand molecules, respectively, yet longer rod-length of 
PMs from lower PLys DP may suggest their disadvantageous property in obtaining efficient 
transfection. Eventually, a concern may arise that the achievement of PMs arriving at target sites by the 
end of long systemic journey may result in precluded transfection. These arguments raise a need of 
comprehensive study taking each structural feature into consideration for attaining an ultimate PM 
formulation. In view of this necessity, this study aimed to seek the most appreciable formulation for 
elevating transfection efficiency on basis of precise structural control of PMs by varying PLys DP with 
particular focus on stability, PEG crowdedness, and rod-length, to fully utilize the benefits of the cross-
linking and cyclic RGD (Arg–Gly–Asp) (cRGD) peptide as ligand for specific integrin-mediated 
uptake. As the cRGD ligand effect was particularly pronounced for the PMs with high PEG shielding, 
21 kDa PEG was used in this study instead of previously used 12 kDa PEG and 17 kDa PEG. The 
present study devoted to clarify the effect of above-mentioned structural features on cellular uptake 
behavior, revealed the presence of critical rod-length for efficient cellular uptake, consequently 
identifying the PM with maximized in vitro transfection efficiency, and its feasibility for systemic gene 
therapy against pancreatic adenocarcinoma, one of the most intractable solid tumors.  
Initially, cross-linking was applied to lower PLys DP of PEG-PLys with an anticipation to 
achieve prolonged blood circulation along with higher PLys DP. Indeed, CPMs of lower PLys DP 
presented prolonged blood circulation than that of higher PLys DP. In order to understand this effect, 
PEG density (σ) should be calculated as it determines the extent of opsonin adsorption and thus RES 
elimination from bloodstream. However, direct estimation of σ is technically difficult for CPMs. In this 
case, rod-length distribution of non-CPMs and CPMs of corresponding PLys DP should be similar, 
because rod-length is a function of σ. Thus, the rod-length distributions of CPMs and non-CPMs of 
respective PLys DP were examined from TEM images and confirmed that they presented almost 
similar distribution. Accordingly, it may be reasonable to consider that the σ of CPMs of corresponding 
PLys DP was similar to that of non-CPMs. σ of non-CPMs was thus inferred to CPMs of 
corresponding PLys DP, giving 0.072, 0.054, and 0.045 chains/nm2 for PLys 20, 42, and 69, 
respectively, suggesting that lower PLys DP indeed retained higher σ. Furthermore, PEG height (H) 
observation from cryo-TEM approved similar PEG height for CPMs and non-CPMs at corresponding 
PLys DP, directly supporting their similar σ. From σ analysis, it is likely that PMs of PLys 69 (lower 
σ) retain mushroom PEG while PMs of PLys 20 (higher σ) retain squeezed PEG. Indeed, PMs of PLys 
69 retain H from cryo-TEM is 13.1 ± 1.3 nm, which numerically agrees with theoretical H of PEG 
mushroom (= 2Rg = 13.0 nm for PEG Mw 21 kDa) while PLys 20 exhibited higher value than 
mushroom H (H from cryo-TEM = 17.8 ± 3.0 nm), suggesting PEG chains were in squeezed 
conformation. Possibly, improved blood circulation of PMs of PLys 20 might be due to eliminating 
RES-mediated clearance because squeezed PEG experience less opsonization while PMs of PLys 69 
with mushroom PEG were more susceptible to opsonization, thus removed by RES.  
Prolonged circulation time was accomplished for CPMs prepared from PLys 20. However, it 
is necessary to see their feasibility for transfection efficiency. In this regard, cellular uptake was 
initially examined for non-CPMs and compared to CPMs. CPMs exhibited higher cellular uptake than 
that of non-CPMs irrespective PLys DP, yet CPMs of PLys 20 exhibited limited cellular uptake 
compared to other PLys DP, suggesting that there should be other issues that limit the cellular uptake 
aside from unfavorable dissociation. Possibly, higher σ of PLys 20 may account for lower cellular 
uptake as a result of diminished interactions with cell membrane. Additionally, there is another issue to 
be considered for cellular uptake is rod-lengh as PLys DP modulates not only σ but also rod-length 
distribution. The CPMs of lower PLys DP presented longer rod-length distribution while that of higher 
PLys DP presented shorter rod length distribution. The longer rod-length may be a problem for 
efficient cellular uptake because the process of each endocytosis has upper size limit with regard to 
their vesicle diameter. Since HeLa cells are generally considered as non-phagocytic cells, the 
possibility of phagocytosis can be excluded. Then, the following four possible endocytic pathways 
could be considered: macropinocytosis, clathrin-, caveolae-dependent, and clathrin/caveolae-
independent endocytosis with upper size limit of endocytic vesicles to be 5 μm, 200 nm, 80 nm, and 90 
nm, respectively. Note that pDNA within PMs is packaged into rod-shaped structure with specific rod-
length distribution based on characteristic quantized folding. Referring the rod-length distribution 
obtained from TEM images, CPMs of PLys 20 loading pCAG-Luc2, majority of rod-length fraction 
was found to be above 200 nm, leaving a very small fraction below 200 nm. Taking this observation 
into consideration, limited cellular uptake of CPMs of PLys 20 may be reasonable because most of the 
fraction has to rely on only macropinocytosis. On the other hand, CPMs of PLys 69 presenting their 
entire fraction below 200 nm may take all four endocytic pathways. This analysis clearly pointed out 
that the rod-length of PMs was also accountable for determining cellular uptake behavior. In order to 
gain further insight on structural feature contributing for the cellular uptake behavior among σ and rod-
length, CPMs with different rod-length distribution but retaining comparable σ were prepared by using 
fixed PLys 20 (which provided highest σ) and three differently sized pDNAs (pKF18: 2204 bp, pCAG-
Luc2: 6477 bp, and pAUR316: 11613 bp). As evidenced from the rod length distribution, it was found 
that pKF18 DNA retained shorter rod length distribution with major fraction below 200 nm while 
pAUR316 DNA retained longer rod length distribution with entire fraction above 200 nm. The similar 
PEG density of these CPMs of differently sized pDNAs was suggested from similar folding number 
pattern as the folding number determines the rod length in the quantized folding scheme of pDNA and 
it is a function of PEG density. The cellular uptake efficiency of these CPMs showed substantial rod-
length dependence; shorter rod CPMs of pKF18 DNA appeared to be more readily internalized into the 
cells while longer rod CPMs of pAUR316 DNA exhibited limited uptake, suggesting that the rod-
length of PMs obviously played crucial contribution in determining cellular uptake efficiency. 
Particular interest was that the critical rod-length found to be 200 nm for efficient cellular uptake. In 
order to further promoting cellular uptake, cRGD peptide ligands were installed onto PMs and the 
cellular uptake was examined against HeLa cells, characterized with over expression of cRGD-specific 
αvβ3 and αvβ5 integrin receptors. The promoted cellular uptake was obtained for all series of CPMs 
regardless of PLys DP and pDNA size approving significant effect of cRGD conjugation to promote 
the cellular uptake. Despite, CPMs of PEG-PLys21(SH) equipped with cRGD (R-PEG-PLys21(SH)), 
still remained lower cellular uptake than that of other PLys DP with cRGD. This observation again 
confirmed that the rod length is an important structural parameter to be primarily considered to achieve 
high cellular uptake. Responding to cellular uptake study, transfection efficiency was evaluated using 
reporter gene Luc (pCAG-Luc2 DNA). CPMs showed significantly elevated gene expression efficiency 
than that of non-CPMs. PMs with cRGD ligand also exhibitedhigher gene expression efficiency than 
that of non-cRGD counterparts. Synergistically, PMs modified with both cross-linking and cRGD 
ligand significantly augmented gene expression efficiency. Ultimately, after meeting the critical rod-
length requirement to be below 200 nm, the cRGD installed CPMs of PEG-PLys69(SH) (R-PEG-
PLys69(SH)) exhibited the highest transfection efficiency among other examined PMs and also 
presented comparable transfection efficiency as like commercial transfection reagents: ExGen 500 and 
Lipofectamine® LTX with PLUS™, despite these PMs are covered with PEG palisade and do not 
possess any specific endosomal escape function. 
The PM formulation with maximized in vitro transfection efficiency i.e., R-PEG-PLys69(SH) 
was challenged to see its feasibility to treat BxPC3-human pancreatic adenocarcinoma based on 
antiangiogenic approach using a gene encoding for potent antiangiogenic exogenous protein, soluble 
fms-like tyrosine kinase-1 (sFlt-1) via trapping vascular endothelial growth factor (VEGF). The 
therapeutic activity of PMs loading either sFlt-1 or Luc pDNA (control) followed by intravenous 
injection was evaluated by tumor growth inhibition study. Significant suppression of tumor growth was 
achieved for sFlt-1 treated group compared to the control group, validating the feasibility of R-PEG-
PLys69(SH) as a formulation for systemic gene therapy. The resulted antitumor activity was confirmed 
by remarkable sFlt-1 protein expression at tumor site. Presumably, the secreted sFlt-1 captured the 
VEGF and limited the access to bind with VEGF receptor-1, preventing the endothelial cell 
proliferation, consequently inhibited neovasculature formation (antiangiogenesis). Indeed, the 
inhibition of neovascularization was confirmed by reduced vascular density of tumor treated with sFlt-
1 loaded R-PEG-PLys69(SH) than that of control group (HEPES). It is noteworthy that PMs of PEG-
PLys21(SH) presented higher σ and exhibited prolonged blood circulation. Accordingly, effective 
antitumor efficacy can be readily anticipated for R-PEG-PLys21(SH) by virtue of an increased chances 
of the PMs to be accumulated at targeted tumor site. However, this formulation did not show antitumor 
efficacy even though PEG-PLys21(SH) showed better blood circulation than PEG-PLys69(SH). Most 
likely, the inferior cellular uptake for PMs of R-PEG-PLys21(SH) due to their longer rod-length 
character as found in in vitro study may resulted in limited transfection at the targeted cells. Indeed, 
neither sFlt-1 expression nor decreased vascular density was observed for R-PEG-PLys21(SH) at the 
tumor site. This result again validated the significance of regulation of rod-length of PMs around 200 
nm in order to promote in vivo gene transfection upon systemic administration, concurrently suggesting 
subsequent research direction to attain ideal systemic gene delivery system, conjoined with prolonged 
blood circulation capacity on R-PEG-PLys69(SH) formulation.  
Taking above-mentioned message into consideration, a CPM formulation satisfying prolonged blood 
circulation with high transfection efficiency was further developed using high Mw 80 kDa PEG and 
PLys 69. High Mw 80 kDa PEG was used to pursue high PEG shielding by increasing PEG height of 
the PM surface and thus anticipating better blood circulation. Indeed, extended blood circulation period 
was attained for PMs of 80 kDa PEG compared to PMs of 21 kDa PEG with the same PLys DP of 69. 
PLys 69 was used to obtain shorter rod-lengths, as it packages pDNA with high folding number based 
on quantized folding. Indeed, entire rod-length fraction was found to be below 200 nm and 
consequently resulting in high transfection efficiency. Therefore, further development by equipping 
appropriate ligand molecules onto well-defined PM with high PEG crowdedness for prolonged blood 
circulation and appropriate packaging size for efficient transfection efficiency should confer tempting 
perspective to accomplish potent therapeutic efficacy towards targeted systemic gene therapy. 
In summary, this study clarifies the role of structural features of PMs such as stability, σ, and 
rod-length on cellular uptake, however most significant feature affecting cellular uptake was found to 
be rod-length. With a critical rod-length around 200 nm, PMs of longer rod showed limited uptake 
while PMs of shorter rod showed efficient uptake. In particularly, coupling with cross-linking and 
cRGD ligand substantially improved the cellular uptake. Consequently, the PM formulation satisfying 
all these features, i.e., R-PEG-PLys69(SH), showed promoted transfection efficiency almost 
comparable to commercial transfection agents, despite the PMs do not have any specific endosomal 
escape function and also covered by PEG. The identified R-PEG-PLys69(SH), exhibited potent tumor 
growth suppression as a result of induced antiangiogenesis. Noteworthy, the CPMs of PEG-
PLys21(SH), presented most of their rod-lengths above 200 nm, resulted in negligible antitumor 
efficacy even they showed better blood retention profile than that of PEG-PLys69(SH), approving 
critical role of rod-length even at in vivo gene transfection. Finally, prolonged blood circulation was 
further conjoined to the CPMs of PEG-PLys69(SH) using high Mw 80 kDa PEG. This well-defined 
CPM formulation featured with prolonged blood circulation and high transfection efficiency may serve 
as potential platform for versatile use in the treatment of variety of intractable diseases by assigning 
specific ligands onto the surface of PMs for targeted systemic gene therapy. 
